|本期目录/Table of Contents|

[1]杨沛轩,农育新,陈闽霞,等.手术对广泛期小细胞肺癌患者生存的影响：基于SEER数据库的倾向得分匹配分析[J].天津医科大学学报,2021,27(01):36-42.
　YANG Pei-xuan,NONG Yu-xin,CHEN Min-xia,et al.Effect of surgery on survival in patients with extensive small cell lung cancer:a SEER database-based propensity scores matching analysis[J].Journal of Tianjin Medical University,2021,27(01):36-42.
点击复制

手术对广泛期小细胞肺癌患者生存的影响：基于SEER数据库的倾向得分匹配分析(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
27卷
期数:
2021年01期
页码:
36-42
栏目:
临床医学
出版日期:
2021-01-20

文章信息/Info

Title:
Effect of surgery on survival in patients with extensive small cell lung cancer:a SEER database-based propensity scores matching analysis
文章编号:
1006-8147（2021）01-0036-07
作者:
杨沛轩1; 农育新1; 陈闽霞1; 张莉芊1; 郑晓滨2
1中山大学中山医学院，广州510000；2中山大学附属第五医院呼吸内科，珠海519000
Author(s):
YANG Pei-xuan1;  NONG Yu-xin1;  CHEN Min-xia1;  ZHANG Li-xian1;  ZHENG Xiao-bin2
1. Sun Yat-Sen School of Medicine，Sun Yat-Sen University，Guangzhou 510000，China；2. Department of Respiratory Medicine，The Fifth Affiliated Hospital of Sun Yat-Sen University，Zhuhai 519000，China
关键词:
小细胞肺癌; 倾向得分匹配; 手术; 预后
Keywords:
extensive stage small cell lung cancer;  propensity score matching;  surgery;  prognosis
分类号:
R563.9
DOI:
-
文献标志码:
A
摘要:
目的：探讨手术治疗与非手术治疗对广泛期小细胞肺癌（ES-SCLC）患者的影响。方法：收集SEER数据库2004—2015年共24 677例ES-SCLC患者并将其分为手术组和非手术组，通过倾向得分匹配分析消除两组间的偏差，用Kaplan-Meier生存分析比较两组的生存情况，利用Log-rank单因素分析和多因素Cox回归对ES-SCLC患者进行校正并进行亚组分层分析。结果：倾向得分匹配后各有249例患者纳入手术组和非手术组，两组Kaplan-Meier生存曲线显示手术组预后较好且有统计学意义（χ2=13.367，P<0.001）。手术组中，接受肺叶切除术者比接受肺段、全肺切除术者预后生存率更佳（χ2=16.447，P<0.001）。单因素和多因素分析结果显示，手术治疗是影响ES-SCLC患者预后的因素（χ2=13.367，P<0.001）。亚组分析显示，≥60岁、N0和N1的手术组患者预后优于非手术组（χ2=8.974、7.732、4.077，P=0.003、0.005、0.043），同时，无论是否化疗，手术组预后均优于非手术组（χ2=8.072、4.104，P=0.004、0.043）。结论：手术总体上可以延长ES-SCLC患者的生存时间。
Abstract:
Objective: To investigate the effect of surgical treatment and non-surgical treatment on the prognosis of patients with extensive stage small cell lung cancer（ES-SCLC）. Methods：A total of 24 677 ES-SCLC patients from 2004 to 2015 were collected from SEER database and divided into surgery group and non-surgery group. Deviation between the two groups was eliminated by tendency score matching analysis. Survival of the two groups was compared by Kaplan-Meier survival analysis. The subgroup analysis was corrected and analyzed by Log-rank univariate analysis and multivariate Cox regression. Results：After propensity score matching，surgery group and non-surgery group each involved 249 patients. The difference between the two Kaplan-Meier survival curves was statistically significant （χ2=13.367，P＜0.001）. In surgery group，patients with pulmonary lobectomy had a better survival rate than those who received segmentectomy or pneumonectomy（χ2=16.447，P＜0.001）. Univariate and multivariate analysis showed surgery was an independent prognostic factor in patients with ES-SCLC（χ2=13.367，P＜0.001）. In subgroup analysis，patients aged 60 or more and with stage N0 and N1 in surgery group had better prognosis than those in non-surgery group（χ2=8.974，7.732，4.077，P=0.003，0.005，0.043）. Meanwhile，regardless of whether patients received chemotherapy，there was difference between prognosis of surgery group and non-surgery group（χ2=8.072，4.104，P=0.004，0.043）and the former was better. Conclusion：In general，the operation can prolong the survival time of ES-SCLC patients.

参考文献/References:

[1] Ge L N，Yan L，Li C，et al. Bavachinin exhibits antitumor activity against nonsmall cell lung cancer by targeting PPARgamma[J]. Mol Med Rep，2019，20（3）：2805
[2] Wang C，Yang D，Zhang X，et al. Association of PTEN gene SNPs rs2299939 with PFS in patients with small cell lung cancer treated with early radiotherapy[J]. Front Genet，2020，11：298
[3] 陈克能. 小细胞肺癌与TNM分期[J]. 中国肺癌杂志，2016，19（6）：409
[4] Fruh M，De Ruysscher D，Popat S，et al. Small-cell lung cancer （SCLC）： ESMO clinical practice guidelines for diagnosis，treatment and follow-up[J]. Annals of Oncology，2013，24（suppl 6）：i99
[5] Carvajal-Hausdorf D，Altan M，Velcheti V，et al. Expression and clinical significance of PD-L1，B7-H3，B7-H4 and TILs in human small cell lung cancer （SCLC）[J]. J Immunother Cancer，2019，7（1）：65
[6] Stinchcombe T E. Current treatments for surgically resectable，limited-stage，and extensive-stage small cell lung cancer[J]. Oncologist，2017：2017
[7] Du X，Tian D，Liu L，et al. Surgery in patients with small cell lung cancer： a period propensity score matching analysis of the Seer database，2010-2015[J]. Oncol Lett，2019，18（5）：4865
[8] Low M，Ben-Or S. Thoracic surgery in early-stage small cell lung cancer[J]. Thorac Surg Clin，2018，28（1）：9
[9] Yang C J，Chan D Y，Shah S A，et al. Long-term survival after surgery compared with concurrent chemoradiation for node-negative small cell lung cancer[J]. Ann Surg，2018，268（6）：1105
[10] Zhao H，Ren D，Liu H，et al. Comparison and discussion of the treatment guidelines for small cell lung cancer[J]. Thorac Cancer，2018， 9（7）：769
[11] Zhang C，Li C，Shang X，et al. Surgery as a potential treatment option for patients with stage Ⅲsmall-cell lung cancer： a propensity score matching analysis[J]. Front Oncol，2019，9：1339
[12] Che K，Shen H，Qu X，et al. Survival outcomes for patients with surgical and non-surgical rreatments in stages I-Ⅲsmall-cell lung cancer[J]. J Cancer，2018，9（8）：1421
[13] Xu L，Zhang G，Song S，et al. Surgery for small cell lung cancer： a Surveillance，Epidemiology，and End Results（SEER） survey from 2010 to 2015[J]. Medicine （Baltimore），2019，98（40）：e17214
[14] Liu Y，Shan L，Shen J，et al. Choice of surgical procedure - lobectomy，segmentectomy，or wedge resection - for patients with stage T1-2N0M0 small cell lung cancer：a population-based study[J]. Thorac Cancer，2019，10（4）：593
[15] Gu C，Huang Z，Dai C，et al. Prognostic analysis of limited resection versus lobectomy in stage IA small cell lung cancer patients based on the surveillance，epidemiology，and end results registry database[J]. Front Genet，2018，9：568
[16] Schreiber D，Rineer J，Weedon J，et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer： should its role be re-evaluated?[J]. Cancer，2010，116（5）：1350
[17] Corkum M T，Rodrigues G B. Patient selection for thoracic radiotherapy in extensive-stage small-cell lung cancer[J]. Lung Cancer Management，2017，6（2）：47

相似文献/References:

[1]李家腾,宋世辉,王 田,等.小细胞肺癌患者化疗前后CEA、NSE和CYFRA21-1的变化对评估预后的作用[J].天津医科大学学报,2014,20(06):448.
　LI Jia-teng,SONG Shi-hui,WANG Tian,et al.Effect of Changes of CEA, NSE and CYFRA21-1 before and after chemotherapy on the evaluation of prognosis in patients with small cell lung cancer[J].Journal of Tianjin Medical University,2014,20(01):448.
[2]王子乔,张雪茜,孟凡荣,等.小鼠小细胞肺癌模型的建立[J].天津医科大学学报,2018,24(01):29.
　WANG Zi-qiao,ZHANG Xue-xi,MENG Fan-rong,et al.Establishment of a mouse model of pulmonary small cell lung cancer[J].Journal of Tianjin Medical University,2018,24(01):29.
[3]张姝阳,张家丽,赵 宁,等.IP方案与CAO方案二线治疗复发小细胞肺癌的疗效及毒副作用比较研究[J].天津医科大学学报,2018,24(05):415.
　ZHANG Shu-yang,ZHANG Jia-li,ZHAO Ning,et al.Comparison of the efficacy and toxicity between the IP regimen and the CAO regimen in the second line treatment for recurrent small cell lung cancer[J].Journal of Tianjin Medical University,2018,24(01):415.
[4]董傲然,张家丽,任秀宝,等.促胃泌素释放肽前体对小细胞肺癌的诊断价值[J].天津医科大学学报,2019,25(03):234.
　DONG Ao-ran,ZHANG Jia-li,REN Xiu-bao,et al.Diagnosis value of pro-gastrin-releasing peptide precursor for small cell lung cancer[J].Journal of Tianjin Medical University,2019,25(01):234.
[5]赵军华,邱鸣寒,袁智勇.射波刀治疗小细胞肺癌脑转移的疗效分析[J].天津医科大学学报,2019,25(04):346.
　ZHAO Jun-hua,QIU Ming-han,YUAN Zhi-yong.The effectiveness of CyberKnife for brain metastases from small cell lung cancer[J].Journal of Tianjin Medical University,2019,25(01):346.
[6]胡 雪 综 述,张新伟 审 校.小细胞肺癌合并低钠血症的研究进展[J].天津医科大学学报,2019,25(04):422.
[7]孙基峰,罗 婧,徐利明,等.广泛期小细胞肺癌肝转移治疗模式探讨[J].天津医科大学学报,2019,25(06):577.
　SUN Ji-feng,LUO Jing,XU Li-ming,et al.Discussion on the treatment mode of liver metastasis in patients with extensive small cell lung cancer[J].Journal of Tianjin Medical University,2019,25(01):577.

备注/Memo

备注/Memo:
基金项目 广东省医学科学技术研究基金（A2020176）；中山大学2019年度高校基本科研业务费青年教师培育项目（19ykpy51）
作者简介 杨沛轩（2000-），男，学士在读，研究方向：临床医学；农育新（1997-），男，学士在读，研究方向：临床医学；通信作者：郑晓滨，E-mail：zhxbin@sysu.edu.cn。杨沛轩和农育新为共同第一作者。
更新日期/Last Update: 2021-01-10